ライフサイエンスコーパス: chimeric antigen receptor

1 the prostate-specific membrane antigen by a chimeric antigen receptor.

2 and bone marrow and continued to express the chimeric antigen receptor.

3 o exploit this by developing a MUC1-specific chimeric antigen receptor.

4 or today's targeted immune interventions and chimeric antigen receptors.

5 ity or to block iKIRs, or by transduction of chimeric antigen receptors.

6 ologous T cells transduced with an anti-CD19 chimeric antigen receptor, after myeloablative chemother

7 ng transfer of T cells engineered to express chimeric antigen receptors against CD19 in B-cell malign

8 ors that coordinately express tumor-specific chimeric antigen receptors and huEGFRt, we show that huE

9 ion molecules (eg, T-cell receptors and CD19 chimeric antigen receptors), and discuss its potential i

10 study, we have engineered an FVIII-specific chimeric antigen receptor (ANS8 CAR) using a FVIII-speci

11 a mesothelin tumor vaccine and a mesothelin- chimeric antigen receptor are being evaluated in the cli

12 in adult and pediatric patients who received chimeric antigen receptor-based adoptive T-cell immunoth

13 s paved the way for clinical applications of chimeric antigen receptor-based therapies.

14 Kochenderfer et al show that engineered CD19-chimeric antigen receptor (CAR) and donor-derived alloge

15 r et al. (2016) find that costimulation by a chimeric antigen receptor (CAR) can control T cell metab

16 T cells expressing a chimeric antigen receptor (CAR) can produce dramatic res

17 antitumor properties, making them attractive chimeric antigen receptor (CAR) carriers for redirected

18 rate CD70-specific T cells, we constructed a chimeric antigen receptor (CAR) consisting of the CD70 r

19 etically modified to express a CD20-targeted chimeric antigen receptor (CAR) demonstrating both safet

20 of T cells to SLAMF7 through expression of a chimeric antigen receptor (CAR) derived from the huLuc63

21 Adoptive immunotherapy using chimeric antigen receptor (CAR) expressing T cells targe

22 nation, immune checkpoint blockage (ICB) and chimeric antigen receptor (CAR) for T-cell-based adoptiv

23 transfer of T cells engineered to express a chimeric antigen receptor (CAR) has emerged as a powerfu

24 f autologous T cells engineered to express a chimeric antigen receptor (CAR) has emerged as a promisi

25 ave been modified to express a CD19-specific chimeric antigen receptor (CAR) have antitumor activity

26 eneration 4-1BB costimulatory-molecule-based chimeric antigen receptor (CAR) in which targeting was a

27 unotherapy retargeting T cells to CD19 via a chimeric antigen receptor (CAR) is an investigational tr

28 etically modified to express a CD19-specific chimeric antigen receptor (CAR) is effective for treatin

29 CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effe

30 Chimeric antigen receptor (CAR) modified T cells targeti

31 composed of T cells engineered to express a chimeric antigen receptor (CAR) offer an attractive stra

32 therapeutic efficacy of T cells expressing a chimeric antigen receptor (CAR) represents an important

33 ive transfer of T cells with a CD19-specific chimeric antigen receptor (CAR) shows remarkable clinica

34 en seen with T cells engineered to express a chimeric antigen receptor (CAR) specific for CD19, a dif

35 by their native receptor while expressing a chimeric antigen receptor (CAR) specific for CD30, a mol

36 Human T cells engineered to express a chimeric antigen receptor (CAR) specific for folate rece

37 ptive resistance compromises the efficacy of chimeric antigen receptor (CAR) T cell therapies, which

38 The recent clinical success of chimeric antigen receptor (CAR) T cell therapy for B cel

39 Chimeric antigen receptor (CAR) T cell therapy has shown

40 has been re-energized by the application of chimeric antigen receptor (CAR) T cell therapy in cancer

41 Immunotherapies with chimeric antigen receptor (CAR) T cells and checkpoint i

42 Chimeric antigen receptor (CAR) T cells can produce dura

43 In this study, chimeric antigen receptor (CAR) T cells expressing EGFRv

44 Transitioning CD19-directed chimeric antigen receptor (CAR) T cells from early-phase

45 tion of B-cell malignancies, the efficacy of chimeric antigen receptor (CAR) T cells has been limited

46 Adoptive immunotherapy utilizing chimeric antigen receptor (CAR) T cells has demonstrated

47 Chimeric antigen receptor (CAR) T cells have been highly

48 Chimeric antigen receptor (CAR) T cells have proven that

49 nt antileukemia efficacy of CD123-redirected chimeric antigen receptor (CAR) T cells in preclinical h

50 Success with chimeric antigen receptor (CAR) T cells offers an opport

51 safety and activity of genetically modified chimeric antigen receptor (CAR) T cells present the oppo

52 ducted the first-in-humans clinical trial of chimeric antigen receptor (CAR) T cells targeting BCMA.

53 Chimeric antigen receptor (CAR) T cells targeting CD19 m

54 Adoptive transfer of high-affinity chimeric antigen receptor (CAR) T cells targeting hemato

55 mphomas in vivo, we engineered CD19-targeted chimeric antigen receptor (CAR) T cells that produce sol

56 ancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cells to show that CD2

57 Extending the success of chimeric antigen receptor (CAR) T cells to T-cell malign

58 cells, by adoptive transfer of FAP-targeted chimeric antigen receptor (CAR) T cells, reduced extrace

59 -TRBC immunotherapy, we developed anti-TRBC1 chimeric antigen receptor (CAR) T cells, which recognize

60 A key to the success of chimeric antigen receptor (CAR) T-cell based therapies g

61 Chimeric antigen receptor (CAR) T-cell therapy is an eme

62 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly

63 iloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed e

64 ically modified to express an antibody-based chimeric antigen receptor (CAR) targeted against the CD1

65 d human T cells were engineered to express a chimeric antigen receptor (CAR) targeted against VEGFR-2

66 kemic activity by transgenic expression of a chimeric antigen receptor (CAR) targeting CD19 expressed

67 ic T cells genetically modified to express a chimeric antigen receptor (CAR) targeting the B-cell ant

68 T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell ant

69 imitation by designing a non-MHC-restricted, chimeric antigen receptor (CAR) targeting the high molec

70 ine induced pluripotent stem cell (iPSC) and chimeric antigen receptor (CAR) technologies to generate

71 T cells genetically engineered to express a chimeric antigen receptor (CAR) that recognized the B-ce

72 reported with the use of T cells modified by chimeric antigen receptor (CAR) that target CD19 in B-ce

73 and colleagues transduced human Tregs with a chimeric antigen receptor (CAR) that targets the HLA cla

74 Chimeric antigen receptor (CAR) therapy targeting CD19 h

75 obtained with engineered T cells, including chimeric antigen receptor (CAR) therapy, call for furthe

76 We and others have introduced a chimeric antigen receptor (CAR) to enable T cells to rec

77 re genetically modified ex vivo to express a chimeric antigen receptor (CAR) to redirect specificity

78 njections of T cells engineered to express a chimeric antigen receptor (CAR) with high specificity, b

79 T cells genetically modified to express a chimeric antigen receptor (CAR), which recognizes a tumo

80 Chimeric antigen receptor (CAR)-engineered T cells (CAR-

81 h recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)-engineered T cells targe

82 Adoptive T-cell therapy with anti-CD19 chimeric antigen receptor (CAR)-expressing T cells is a

83 Chimeric antigen receptor (CAR)-modified adoptive T-cell

84 Adoptive transfer of chimeric antigen receptor (CAR)-modified immune cells ha

85 mentation by highlighting the application of chimeric antigen receptor (CAR)-modified T cells in canc

86 etion chemotherapy followed by CD19-specific chimeric antigen receptor (CAR)-modified T cells is a re

87 y of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor (CAR)-modified T cells targeti

88 nstrating that treatment with CD19-specific, chimeric antigen receptor (CAR)-modified T cells that ar

89 the systemic administration of HER2-specific chimeric antigen receptor (CAR)-modified virus-specific

90 ity of adoptively transferred, CD19-specific chimeric antigen receptor (CAR)-redirected cytotoxic T l

91 The clinical efficacy of chimeric antigen receptor (CAR)-redirected T cells remai

92 Adoptive transfer of chimeric antigen receptor (CAR)-redirected T lymphocytes

93 ical trials have shown promise in the use of chimeric antigen receptor (CAR)-transduced T cells; howe

94 genetically modified to express an anti-CD19 chimeric antigen receptor (CAR).

95 ls transduced to express an antigen-specific chimeric antigen receptor (CAR-T) containing an intracel

96 of T lymphocytes expressing a CD19-specific chimeric antigen receptor (CAR.CD19) induces complete tu

97 ined if T cells grafted with a HER2-specific chimeric antigen receptor (CAR; HER2-specific T cells) r

98 using T cells that are programmed to express chimeric antigen receptors (CAR T cells) consistently pr

99 Chimeric antigen receptors (CAR) are clinically translat

100 Chimeric antigen receptors (CAR) combine an antigen-bind

101 rgeting by human T cells modified to express chimeric antigen receptors (CAR) due to potential for de

102 herapy using autologous T cells endowed with chimeric antigen receptors (CAR) has emerged as a powerf

103 genetically modified to express single-chain chimeric antigen receptors (CAR) have shown promise in e

104 Human T lymphocytes were transduced with chimeric antigen receptors (CAR) specific for either hPS

105 uman T cells genetically modified to express chimeric antigen receptors (CAR) specific to the B cell

106 d clinical application of T cells expressing chimeric antigen receptors (CAR).

107 This report describes a novel CD4-based "chimeric antigen receptor" (CAR) which, when genetically

108 antigen receptor T cells redirected to CD19 (chimeric antigen receptor [CAR19]) show great promise in

109 Two methods have emerged: the Chimeric Antigen Receptors (CARs) and T-cell Receptor (T

110 can be harnessed to segregate expression of chimeric antigen receptors (CARs) and TCRs between devel

111 Although T cells expressing CD19-specific chimeric antigen receptors (CARs) are a promising new th

112 ered T lymphocytes expressing tumor-directed chimeric antigen receptors (CARs) are designed to benefi

113 to specific antigen targets with engineered chimeric antigen receptors (CARs) are emerging as powerf

114 Chimeric antigen receptors (CARs) are fusion proteins in

115 Chimeric antigen receptors (CARs) are synthetic receptor

116 Chimeric antigen receptors (CARs) are synthetic receptor

117 Although the use of chimeric antigen receptors (CARs) based on single-chain

118 Recent clinical trials demonstrated that chimeric antigen receptors (CARs) can effectively redire

119 For example, synthetic chimeric antigen receptors (CARs) can redirect T cells t

120 Therefore, we developed 2 chimeric antigen receptors (CARs) containing a CD123-spe

121 Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate potent cli

122 Genetically modified T cells expressing chimeric antigen receptors (CARs) demonstrate robust res

123 ostimulatory properties of second-generation chimeric antigen receptors (CARs) determine the overall

124 Chimeric antigen receptors (CARs) direct tumor cell reco

125 of genes encoding T-cell receptors (TCRs) or chimeric antigen receptors (CARs) directed against tumor

126 We generated MHC-independent chimeric antigen receptors (CARs) directed to the GD2 an

127 netically modified to express tumor-specific chimeric antigen receptors (CARs) enabled us to show in

128 Unlike the physiologic T-cell receptor, chimeric antigen receptors (CARs) encompass immunoglobul

129 he transfer of T cells engineered to express chimeric antigen receptors (CARs) for a specific cell-su

130 Investigators developed chimeric antigen receptors (CARs) for expression on T ce

131 The successful use of chimeric antigen receptors (CARs) for the generation of

132 ng of TCR signaling, T cells engineered with chimeric antigen receptors (CARs) have been remarkably s

133 Advances in the design of chimeric antigen receptors (CARs) have improved the anti

134 Chimeric antigen receptors (CARs) have shown great promi

135 T cells expressing antigen-specific chimeric antigen receptors (CARs) improve outcomes for C

136 ol T cells engineered to permanently express chimeric antigen receptors (CARs) is a key feature to im

137 mmune targeting of B-cell malignancies using chimeric antigen receptors (CARs) is a promising new app

138 emonstrate that modification of T cells with chimeric antigen receptors (CARs) is a promising strateg

139 Expressing chimeric antigen receptors (CARs) on T cells is a means

140 an be re-directed to kill cancer cells using chimeric antigen receptors (CARs) or T cell receptors (T

141 T cells expressing chimeric antigen receptors (CARs) or the infusion of bis

142 Chimeric antigen receptors (CARs) redirect T cell cytoto

143 lls genetically engineered with FAP-reactive chimeric antigen receptors (CARs) specifically degranula

144 ariable, and early reports of BCMA targeting chimeric antigen receptors (CARs) suggest antigen downre

145 ess highly active T-cell receptors (TCRs) or chimeric antigen receptors (CARs) targeting a variety of

146 pose T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19

147 r of T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 has pro

148 Chimeric antigen receptors (CARs) targeting CD19 have me

149 r of T cells genetically modified to express chimeric antigen receptors (CARs) targeting the CD19 B c

150 Chimeric antigen receptors (CARs) that bind HBV envelope

151 n successfully used to enforce expression of chimeric antigen receptors (CARs) that provide T cells w

152 antigen-specific T-cell receptors (TCRs) or chimeric antigen receptors (CARs) that target a single a

153 cterization of T cells expressing introduced chimeric antigen receptors (CARs) to redirect specificit

154 are genetically modified ex vivo to express chimeric antigen receptors (CARs) to redirect their spec

155 While chimeric antigen receptors (CARs) using single-chain ant

156 T cells with genes encoding disease-specific chimeric antigen receptors (CARs), so that they can comb

157 to T-cells genetically engineered to express chimeric antigen receptors (CARS), when activated periph

158 rgeting T-cell receptors (TCRs) or synthetic chimeric antigen receptors (CARs).

159 cell receptors (TCRs) or non MHC-restricted chimeric antigen receptors (CARs).

160 ced with lentivirus expressing CD19-specific chimeric antigen receptors (CARs).

161 sponses (e.g., monoclonal antibodies [mAbs], chimeric antigen receptors [CARs]).

162 8 T cells genetically engineered to express "chimeric antigen receptors" (CARs) represents a potentia

163 ically engineered to express a CD19-specific chimeric antigen receptor (CD19-CAR).

164 utologous T cells expressing a CD19-specific chimeric antigen receptor (CD19.CAR) are active against

165 ddressed these questions using a NKG2D-based chimeric antigen receptor construct (chNKG2D) in fully i

166 ly, T cells targeted to CD44v6 by means of a chimeric antigen receptor containing a CD28 signaling do

167 gous T cells transduced with a CD19-directed chimeric antigen receptor (CTL019) lentiviral vector in

168 -Barr virus (EBV)-specific CTLs to express a chimeric antigen receptor directed to the diasialogangli

169 re, T lymphocytes expressing both CCR4 and a chimeric antigen receptor directed to the HL associated

170 or-associated cell membrane mucin MUC1 using chimeric antigen receptor-engineered human T cells.

171 strated therapeutic utility as components of chimeric antigen receptor-engineered T cells, further co

172 -1-specific T-cell receptor and GD2-specific chimeric antigen receptor-engineered T-cell proliferatio

173 se and use the systems model to design novel chimeric antigen receptors for therapy.

174 itumor effects in murine T cell receptor and chimeric antigen receptor gene therapy models.

175 In this review, we explain the concept of chimeric antigen receptor gene-modified T cells, describ

176 s antigen-specific T-cell receptors (TCR) or chimeric antigen receptors generates a continual supply

177 to express conventional T cell receptors or chimeric antigen receptors has further extended the succ

178 targeting and activation molecules known as chimeric antigen receptors, have demonstrated powerful p

179 EBV-CTLs expressing both a native and a chimeric antigen receptor may therefore have added value

180 herapy followed by infusion of CD19-specific chimeric antigen receptor-modified (CAR) T cells has pro

181 ated the safety and feasibility of anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therap

182 phodepletion chemotherapy with CD19-targeted chimeric antigen receptor-modified T (CAR-T)-cell immuno

183 Initial success with chimeric antigen receptor-modified T cell therapy for re

184 ry acute lymphoblastic leukemia treated with chimeric antigen receptor-modified T cell therapy on a p

185 anagement of cytokine release syndrome after chimeric antigen receptor-modified T cell therapy.

186 All subjects received chimeric antigen receptor-modified T cell therapy.

187 Chimeric antigen receptor-modified T cells (CAR T cells)

188 Adoptive T-cell therapy using chimeric antigen receptor-modified T cells (CAR-T therap

189 Chimeric antigen receptor-modified T cells are capable o

190 s per kilogram of body weight) of autologous chimeric antigen receptor-modified T cells reinfused int

191 Chimeric antigen receptor-modified T cells targeting CD1

192 Chimeric antigen receptor-modified T cells with specific

193 The recent success of chimeric antigen receptor-modified T lymphocytes in B-ce

194 Chimeric antigen receptor-modified T-cell therapy agains

195 signaling, novel proteasome inhibitors, and chimeric antigen receptor-modified T-cell therapy.

196 I sequences into specific sites in synthetic chimeric antigen receptors or natural T-cell receptors o

197 antibodies or T cells engineered to express chimeric antigen receptors or T-cell receptors (TCRs) ha

198 r therapy with T cells engineered to express chimeric antigen receptors or T-cell receptors.

199 T-cell receptors (TCRs) and chimeric antigen receptors recognizing tumor-associated

200 l antibodies and T cells modified to express chimeric antigen receptors specific for B-cell lineage s

201 Chimeric antigen receptor T (CAR-T) cell therapy has pro

202 Chimeric antigen receptor T (CAR-T) cells have demonstra

203 successes of immune checkpoint blockade and chimeric antigen receptor T cell therapies represent a t

204 ab-BCMA are comparable to those of anti-BCMA chimeric antigen receptor T cell therapy (CAR-T-BCMA), f

205 L survival and increased the efficacy of the chimeric antigen receptor T cell transfer and PD-1 inhib

206 Also known as chimeric antigen receptor T cells (CAR T cells), these e

207 otent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumoma

208 f immune effectors such as antitumor mAb and chimeric antigen receptor T cells bypasses many of the m

209 It remains to be established whether chimeric antigen receptor T cells have clinical activity

210 e B4 inhibitors in pemphigoid disorders, and chimeric antigen receptor T cells in pemphigus.

211 ntly underway, as well as other trials using chimeric antigen receptor T cells or (natural killer/eff

212 he syndrome and did not prevent expansion of chimeric antigen receptor T cells or reduce antileukemic

213 Chimeric antigen receptor T cells redirected to CD19 (ch

214 only other grade 3/4 toxic effect related to chimeric antigen receptor T cells was lymphopenia.

215 In addition, the chimeric antigen receptor T cells were observed in the c

216 body and a T-cell signaling molecule (CTL019 chimeric antigen receptor T cells), at a dose of 1.4x10(

217 trials for hematological malignancies using chimeric antigen receptor T cells.

218 sing mesothelin (CRS-207, JNJ-64041757), and chimeric antigen receptor T-cell therapies.

219 herapy' designation to CTL019, the anti-CD19 chimeric antigen receptor T-cell therapy developed at th

220 as a highly efficient selection epitope for chimeric antigen receptor(+) T cells using biotinylated

221 ly engineered syngeneic T cells expressing a chimeric antigen receptor targeting the VEGF receptor-2

222 We constructed a ROR1-specific chimeric antigen receptor that when expressed in T cells

223 or example, through genetic engineering with chimeric antigen receptors.This meeting report puts pres

224 nt's own T cells with a transgene encoding a chimeric antigen receptor to identify and eliminate CD19

225 lass I-restricted T-cell receptors (TCRs) or chimeric antigen receptors to genetically modify CD8(+)

226 transfer of transgenic T-cell receptors and chimeric antigen receptors to redirect T cell and natura

227 ional curative options such as CD19-targeted chimeric antigen receptors to treat relapsed/refractory

228 y of B-cell malignancies using CD19-targeted chimeric antigen receptor-transduced T cells or CD20-tar

229 specificity of intracellular targeting since chimeric antigen receptors which internalize antigen by

230 We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cel

231 iated cytotoxicity and that T cells carrying chimeric antigen receptors with the antibody variable re